The table below is a review of notable updates that occurred in September 2025.
All articles by Steve Duffy
The following are notable drug approvals that occurred in December 2024.
The FDA has granted Fast Track designation to TSHA-102, an AAV-based gene therapy, for the treatment of Rett syndrome.
In preclinical studies, WP1122 has shown to increase cellular uptake of 2-DG, increase drug half-life, and increase the ability to cross the blood brain barrier.
The Food and Drug Administration (FDA) has granted Orphan Drug Designation to zotiraciclib (Adastra Pharmaceuticals) for the treatment of glioma.
-
Top Picks
from ourHaymarket Medical Network
